echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Medical representatives were investigated for involvement of two pharmaceutical companies

    Medical representatives were investigated for involvement of two pharmaceutical companies

    • Last Update: 2021-05-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    According to the "Administrative Measures for the Recordation of Medical Representatives (Trial)", law enforcement officers filed investigations on the sales activities of medical representatives in pharmacies.


    1.


    1.


    In an interview with reporters from Xin'an Evening News, Anhui Net, and Dawan News, the law enforcement officers of the Xiaoyaojin Market Supervision Office introduced that during routine inspections of the pharmacy, they discovered that an elderly person was measuring blood pressure with the help of the pharmacy staff at the drug business site.


    It is worth noting that the promotional color pages and related drugs are provided by the above-mentioned pharmaceutical companies.


    Therefore, according to the "Administrative Measures for the Recordation of Medical Representatives (Trial)" issued by the State Drug Administration, it is clearly stipulated that medical representatives shall not undertake the task of drug sales.


    In addition, law enforcement officers found a promotional color page of "Niuhuang Qingxin Pills" from a well-known Chinese medicine company at the operation site of the pharmacy, in which the printed "Stroke sequelae improvement and conditioning" and stroke sequelae symptoms improved, and then stroke prevention The medication method is obviously inconsistent with the functions and indications, usage and dosage indicated in the drug insert.


    In combination with the fact that the leaflets and color pages of the two prescription drugs mentioned by the involved pharmacy did not match the contents of the corresponding drug inserts, and the contents of the promotion were not approved by the review authority, the pharmacy was suspected of breaking the law and other circumstances, the pharmacy was filed for investigation.


    2.


    2.


    The main tasks of medical representatives are: formulating medical product promotion plans and programs; delivering medical product-related information to medical staff; assisting medical staff in the rational use of the company's medical products; collecting and feeding back information on the clinical use of drugs and hospital needs.


    At the same time, medical representatives should not have the following behaviors including undertaking sales tasks and participating in the administration:

    Conduct academic promotion and other activities without filing; conduct academic promotion and other activities without the consent of medical institutions; undertake drug sales tasks, implement sales activities such as collection and processing of purchase and sales receipts; count the number of drug prescriptions issued by doctors; mislead doctors to use drugs , Exaggerating or misleading the efficacy, concealing the known adverse reaction information of the drug or concealing the adverse reaction information feedback from the doctor; other intervention or behavior that affects the clinical rational use of the drug.


    There has been a view in the industry that not being able to undertake sales tasks is actually "not participating in the transaction of drug purchase and sale.


    For pharmaceutical companies, the filing system is intended to bring millions of marketers who have been "diving" in the pharmaceutical market all the year round into management-requiring drug marketing authorization holders to be responsible for the filing and management of pharmaceutical representatives, and pharmaceutical companies are therefore also responsible for this.


    Literally, the filing system restricts the promotion of medical representatives in medical institutions, but does not involve the promotion of medical representatives in pharmacies.


    According to the "Measures for the Administration of the Recordation of Medical Representatives (Trial)", the law enforcement officers of the Municipal Supervision and Administration Office filed and investigated the sales activities of medical representatives in pharmacies.


    3.
    Multi-pharmaceutical companies lay out the retail market

    3.
    Multi-pharmaceutical companies lay out the retail market

    With the evaluation of consistency, the introduction of national centralized procurement and other policies-under the background of the gradual deepening of medical reforms, the previously existing "rent-seeking" space has become thinner, especially in the midstream medical circulation and terminal drug sales channels.
    .

    A research report shows that retail pharmacies are the most important drug sales terminal in my country besides hospital terminals.
    In the context of high-volume procurement and increased medical insurance control fees, industrial companies have begun to seek cooperation with more market-oriented retail pharmacies as an out-of-hospital market.
    The only "window" for patients, the channel value of retail pharmacies, especially the channel capacity of prescription drugs has gradually improved.

    As the volume purchase policy has reduced the sales of the winning bidders in the hospital market, most pharmaceutical companies put the development and development of prescription drug retail channels on the agenda, and the out-of-hospital retail market will also become a must for pharmaceutical factories, commercial circulation companies, and chain pharmacies.
    place.

    Take the third batch of centralized procurement as an example.
    In 2019, the terminal drug sales of public medical institutions in China were 137.
    94 billion yuan.
    This centralized procurement covered the top 80% of the drugs, and the market sales involved more than 110 billion yuan.
    The market structure will have a profound impact.

    Bulk purchasing is about to shake up the large plate of medicines belonging to medical institutions.
    In the context of the outflow of prescriptions, there is no doubt that pharmaceutical companies are fancying the retail market.

    Therefore, the expansion of pharmaceutical companies in the out-of-hospital retail market also places higher demands on medical representatives, and the restriction of the filing system on representatives from medical institutions to the out-of-hospital market requires all pharmaceutical companies and medical representatives to be vigilant.

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.